Acasti Pharma Inc ACST

Healthcare

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

NDAQ:ACST - Post by User

Acasti Pharma Inc > COLT study

<< Previous

Bullboard Posts

Next >>

Comment by lscfaon Nov 25, 2019 12:04pm

118 Views

Post# 30389666

RE:COLT study

The logical explanation is it takes time for the body to adjust to an effective dosage of 4g/day.

Stormdog01 wrote: Any theory as to why in the COLT study the group that had 2g for 4 weeks and then 4g for another 4 weeks only managed to get a -13.6% baseline decrease in TGs? It was a sample population of 57, so not so small, but very large difference with the 62 patients group that received 4g for the whole 8 weeks that got -21.6% decrease in baseline TG's.

<< Previous

Bullboard Posts

Next >>

A junior copper-gold stock trading at a bargain of monumental proportions